Related Experiment Video
Updated: Jan 18, 2026
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
MULTICENTER STUDY OF FACTORS ASSOCIATED WITH VISUAL AND ANATOMIC OUTCOMES OF SUPRACHOROIDAL HEMORRHAGE
Tianyu Liu1, Sahal Saleh2, Jason Keil3
1Associated Retinal Consultants, Royal Oak, Michigan.
Purpose:
To report outcomes of suprachoroidal hemorrhage (SCH).
Methods:
Retrospective nonrandomized study of eyes with SCH from two sites (January 1, 2013-December 31, 2022). The primary outcome was the 6-month change in visual acuity (VA). Multivariable analysis was performed, as well as a comparison of matched eyes with and without systemic steroids.
Results:
Overall, 143 eyes of 143 patients (mean age 70.8 years, 52.4% male) were included, with 72 perioperative, 24 traumatic, and 47 spontaneous SCH cases. The mean (SD) presenting VA was 2.07 (0.92) logMAR. 87 (60.8%) were managed nonsurgically, 24 (16.8%) underwent drainage, and 32 (22.4%) underwent drainage and vitrectomy; 36 (25.2%) received systemic steroids. At 6 months, the mean (SD) change in VA from presentation was -0.41 (0.84) logMAR. 102 eyes (71.3%) achieved anatomic success (complete retinal attachment). Concurrent retinal detachment was associated with worse VA change and anatomic success in multivariable analysis ( P < 0.05). In the matching analysis, eyes receiving systemic steroids were more likely to achieve ≥ 3-line gain in VA than matched eyes without systemic steroids (77.8% vs. 55.3%, P = 0.047).
Conclusion:
The visual prognosis of eyes with SCH remains guarded. Systemic steroids may be associated with a modest benefit for visual outcomes. Concurrent retinal detachment portends worse outcomes.
